Fertility device company joins forces with one of the largest IVF clinics in strategic partnership

MedTech News: A provider and manufacturer of medical devices designed to streamline and automate the fertility treatment process, Genea Biomedx, has entered into a strategic partnership that promises to enhance the future of reproductive technology.

Once a part of the Australian fertility group Genea Fertility, Genea Biomedx has operated independently under Basecare Medical since 2023, making this collaboration a significant step forward for both companies to leverage their strengths.

The IVF sector is a lucrative industry with one in every 18 births in Australia now resulting from IVF treatment. Dominating the sector are three major players – Genea, Monash IVF, and Virtus – who collectively generate over 80% of the industry’s revenue. An IVF cycle at one of these clinics typically costs between $10,000 and $12,000, with approximately half of the expense subsidised by taxpayers through Medicare.

Tim Yeoh, CEO of Genea Fertility, said “Genea Fertility and Genea Biomedx share the same vision of being at the forefront of assisted reproductive technology. It is a natural fit for us to continue partnering together to deliver world leading fertility advancements to patients in Australia.”

Since 2015, Genea Fertility has cemented its position as a leader in reproductive science by investing in key medical technologies, such as the Geri timelapse incubator and Gems culture media.

These innovations have set industry standards, particularly with timelapse technology, which Genea has made accessible to all patients, enhancing the experience through its Grow smartphone app that provides video updates on embryo development.

Genea Biomedx CEO, Marian Garriga, emphasised the impact of the partnership on patient outcomes.

“Genea Biomedx is a global leader in comprehensive IVF solutions, dedicated to delivering innovative technologies that empower patients to achieve their dreams of growing their families. Our advanced devices are designed to enhance clinical outcomes by addressing key variables such as human error and environmental factors.

“Our partnership with Genea Fertility will help to continue to advance outcomes for patients, and we look forward to delivering on this together,” she stated.

As part of this collaboration, Genea Fertility will integrate Biomedx’s Genie DNA sequencer technology, boosting lab efficiency with cutting-edge equipment. Selected clinics will also upgrade to Genea Biomedx’s innovative cryostorage tank system, Gelida, offering enhanced performance and reliability.

Further integration includes Guardian, Genea Biomedx’s electronic witnessing system, which improves IVF sample traceability and identification in Genea Fertility laboratories.

This partnership reflects the continued evolution of Genea Fertility. In 2018, Asian investment firm Aldworth Management, Hong Kong-listed financial services and wealth company Mason Group, and Chinese health unicorn WeDoctor – backed by tech giant Tencent – acquired Genea for approximately $300 million.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.